Analyst firms · Leerink Partners · IPHA

Leerink Partners IPHA price target and rating history

Innate Pharma S.A. ADS (IPHA) · Health Care

Leerink Partners rates Innate Pharma S.A. ADS (IPHA) Market Perform with a $1 price target, as of its latest action on Nov 19, 2026. It has published 7 rating actions on IPHA since September 2021, including 4 upgrades and 2 downgrades.

Current rating
Market Perform
Price target
$1
Median target, all firms
Too few
Actions on IPHA
7

Leerink Partners price target on IPHA

$9$5$120222023202420252026
Leerink Partners price target on IPHA, each point a stated target, September 2021 to November 2026.

Every Leerink Partners rating on IPHA

How other firms rate IPHA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersMarket Perform$1Nov 19, 2026
BTIGBuy$8Mar 12, 2026

Questions about Leerink Partners and IPHA

What is Leerink Partners's price target for IPHA?
Leerink Partners's latest stated price target for Innate Pharma S.A. ADS (IPHA) is $1, from its action on Nov 19, 2026.
What is Leerink Partners's rating on IPHA?
Leerink Partners rates IPHA Market Perform, a neutral rating, as of Nov 19, 2026.
When did Leerink Partners last change its view on IPHA?
On Nov 19, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $1.

All Leerink Partners ratingsIPHA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.